There are several shortcomings of this study: First, MAP2K3 expression was only validated at the mRNA level, not at the protein level or cellular level, and ex vivo experiments are needed to further validate the possible signaling pathways involved in MAP2K3 in glioma. Here, MAP2K3 is linked to central nervous system cancer.